RE: TR64 - LSE complaint3 Feb 2021 06:55
JoeyDiamond,
The complaint is valid as the statement is not factual. It has to be made a clear distinction between the paper headlines made by EU politicians their medical bodies. I am bemused to see that you fall for political headlines with the intent to deflect the EU procurement failure.
EU medical body approved the cacine for ALL ages "There are not yet enough results in older participants to provide a figure for how well the vaccine will work in 65+ group. However, protection is expected, given that an immune response is seen in this age group and based on experience with other vaccines," the experts said in a statement; the rest of the data will come from the other trials as FatP and other people correctly stated.
Someone on this forum very cleverly said that the lack of data (yet to be produced) does not mean the lack of evidence.
I had to filter TR64 out as all its posts twist the facts and waste my time to check them, highlight biasly the negative without balancing factors and the most bizarre and questionable is trashing AZN on the GSK message board. Question yourself why TR64 go to such a length to clatter the GSK board trashing AZN with apocalyptic view. If its is so much against AZN it would be advisable to sell the stock and move on.
The flu vaccine efficacy is 40-60% which iswith the AZN published results and most importantly the international standard approval threshold for any vaccine.
I appreciate anyone who will post a legal case against AZN with pro and con's of its merits but not the apocalyptic view that AZN will go under which actually (we will see) it may not even be uphold to start.
Well ...if you do more research you may find out that this is how the short selling works, HFunds hire people to intensely and systematically bash investment boards wit bad news.